Relationship between insulin‐like growth factor‐1 receptor and human papillomavirus in patients with oropharyngeal cancer. Issue 7 (27th June 2014)

• Record Type: Journal Article
• Authors: Matsumoto, Fumihiko; Fujimaki, Mitsuhisa; Ohba, Shinichi; Kojima, Masataka; Yokoyama, Junkichi; Ikeda, Katsuhisa
• Is Part Of: Head & neck. Volume 37:Issue 7(2015:Jul.)
• Page Start: 977
• Page End: 981
• Publication Date: 2014-06-27
• Subjects: Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.23702
• Languages: English
• ISSNs: 1043-3074

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="hed23702-sec-0001" sec-type="section"> <title>Background</title> <p>Human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (SCC) is associated with better prognosis than HPV‐negative oropharyngeal SCC. The purpose of this study was to assess the expression of insulin‐like growth factor‐1 receptor (IGF‐1R) in patients with oropharyngeal SCC, its relationship to HPV status and various clinical parameters, and its relationship with clinical outcome.</p> </sec> <sec id="hed23702-sec-0002" sec-type="section"> <title>Methods</title> <p>The study subjects were 59 patients with oropharyngeal SCC. IGF‐1R expression was examined by immunohistochemistry in paraffin‐embedded tumor tissues. HPV status was evaluated by in situ hybridization (ISH) in the same tissues.</p> </sec> <sec id="hed23702-sec-0003" sec-type="section"> <title>Results</title> <p>IGF‐1R did not correlate with clinical parameters, but IGF‐1R expression was more common in HPV‐negative tumors than in HPV‐positive tumors. The prognosis was poorer in patients of the IGF‐1R‐positive group than in the IGF‐1R‐negative group.</p> </sec> <sec id="hed23702-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The results suggested that IGF‐1R expression in oropharyngeal SCC correlated with poor prognosis in HPV‐negative patients. Treatment targeting IGF‐1R could potentially improve the survival of patients with HPV‐negative oropharyngeal SCC. © 2014 Wiley Periodicals, Inc. Head Neck 37: 977–981, 2015</p> </sec> </abstract>